Critical Review: View (NASDAQ:VIEW) versus Xinyi Glass (OTCMKTS:XYIGF) - Defense World

2022-07-02 07:43:37 By : Mr. Tengyue Tao

Posted by admin on Jun 28th, 2022

View (NASDAQ:VIEW – Get Rating) and Xinyi Glass (OTCMKTS:XYIGF – Get Rating) are both industrial products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

This is a breakdown of current recommendations for View and Xinyi Glass, as reported by MarketBeat.com.

View presently has a consensus price target of $6.00, suggesting a potential upside of 297.35%. Given View’s stronger consensus rating and higher possible upside, equities research analysts plainly believe View is more favorable than Xinyi Glass.

View has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Xinyi Glass has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

This table compares View and Xinyi Glass’ net margins, return on equity and return on assets.

This table compares View and Xinyi Glass’ top-line revenue, earnings per share and valuation.

Xinyi Glass has lower revenue, but higher earnings than View.

75.5% of View shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

View Operating Corporation, a technology company, develops, manufactures, and sells smart building products. Its product portfolio includes View Smart Glass that comprise electrochromic glass panels in the form of insulating glass units; View Net, a cloud-connected network infrastructure offering that can incorporate and power smart building devices; View Immersive Experiences, which transforms View Smart Glass windows into transparent, digital, and interactive surfaces; View Sense modules to measure and optimize light, humidity, temperature, air quality, dust, and noise; and View Smart Protect, an intrusion detection solution that can be deployed on View Smart Glass windows to improve the security of a building by detecting glass breakage. The company is headquartered in Milpitas, California.

About Xinyi Glass (Get Rating)

Xinyi Glass Holdings Limited, an investment holding company, produces and sells automobile, construction, float, and other glass products for commercial and industrial applications. The company operates through three segments: Float Glass, Automobile Glass, and Architectural Glass. It is also involved in the manufacturing and sale of automobile rubber and plastic components, as well as electronic glass; trading of automobile glass; and research and trading of glass. In addition, the company offers logistic and related services; supply chain services; operates a wind farm for electricity generation; and manufactures automatic machines for solar glass factory and other glass related industries, as well as holds properties and car parks. The company serves automobile glass manufacturing; wholesale and distribution; automobile repair; motor vehicle manufacturing; curtain wall engineering and installing; architectural and furniture glass manufacturing; electronic and household appliances manufacturing; and float glass wholesale and distribution companies. It sells its products in approximately 140 countries and territories, including the People's Republic of China, Hong Kong, the United States, Canada, Australia, and New Zealand, as well as countries in Asia, the Middle East, Europe, Africa, and the Americas. The company was founded in 1988 and is headquartered in Kwun Tong, Hong Kong.

Receive News & Ratings for View Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for View and related companies with MarketBeat.com's FREE daily email newsletter.

Contrasting M.D.C. (NYSE:MDC) and Second Street Capital (OTCMKTS:CTON)

Head-To-Head Comparison: Biora Therapeutics (BIOR) vs. Its Peers